http://www.prnewswire.com/cgi-bin/st...4432833&EDATE=
Although trial on hold due to effect on immune system.
Quote:
Analysis of the first co-primary endpoint showed that patients taking
alemtuzumab at high and low doses experienced at least a 75 percent
reduction in the risk for relapse after at least two years of follow up
when compared to patients treated with interferon beta-1a. This difference
was statistically significant in favor of the alemtuzumab patients at both
high and low doses, with a p-value less than the pre-specified value
(p=0.00328) assigned for the two-year interim analysis.
Analysis of the other co-primary endpoint showed that patients taking
alemtuzumab at high and low doses experienced at least a 65 percent
reduction in the risk for progression of clinically significant disability
when compared to patients treated with interferon beta-1a. This difference
was statistically significant in favor of the alemtuzumab patients at both
high and low doses, with a p-value less than the pre-specified value
(p=0.01194) assigned for the two-year interim analysis.
|
09-14-2006, 12:24 PM
Reply With Quote
Campath outperforms Rebif
Linear Mode
